metronidazole has been researched along with HIV Coinfection in 76 studies
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.
metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.
| Excerpt | Relevance | Reference |
|---|---|---|
| "BackgroundBacterial vaginosis (BV) causes genital inflammation and increases HIV risk, whereas a vaginal microbiota dominated by Lactobacillus species is associated with immune quiescence and relative HIV protection." | 7.11 | Metronidazole treatment rapidly reduces genital inflammation through effects on bacterial vaginosis-associated bacteria rather than lactobacilli. ( Armstrong, E; Burke, KE; Castañeda, GR; Coburn, B; Cohen, CR; Crawford, ED; Hemmerling, A; Huibner, S; Kaul, R; Kulikova, M; Liu, R; Miller, S; Morris, SR; Nagelkerke, N; Newmann, SJ; Reno, H, 2022) |
| "In areas with a high prevalence of trichomoniasis, the addition of metronidazole to the syndromic management of male urethritis can eliminate infection with T vaginalis and may help to reduce the transmission of HIV." | 5.10 | Addition of treatment for trichomoniasis to syndromic management of urethritis in Malawi: a randomized clinical trial. ( Chilongozi, D; Cohen, MS; Hobbs, MM; Hoffman, IF; Kaydos-Daniels, SC; Kazembe, P; Kip, E; Martinson, F; Miller, WC; Msowoya, E; Price, MA; Zimba, D, 2003) |
| " The knowledge of adverse effects of antibiotics was greatest for tooth discoloration which is related to tetracycline." | 3.80 | Antibiotics prescription in Nigerian dental healthcare services. ( Azodo, CC; Ojehanon, PI, 2014) |
| "Eleven vertically HIV-infected children with chronic diarrhea were treated with oral gentamicin, metronidazole and cholestyramine for 3 to 5 days." | 3.69 | Antibiotic and cholestyramine treatment of chronic diarrhea in HIV-infected children. ( Altamura, N; Bastoni, K; Fontana, M; Massironi, E; Principi, N; Zuin, G, 1997) |
| "BackgroundBacterial vaginosis (BV) causes genital inflammation and increases HIV risk, whereas a vaginal microbiota dominated by Lactobacillus species is associated with immune quiescence and relative HIV protection." | 3.11 | Metronidazole treatment rapidly reduces genital inflammation through effects on bacterial vaginosis-associated bacteria rather than lactobacilli. ( Armstrong, E; Burke, KE; Castañeda, GR; Coburn, B; Cohen, CR; Crawford, ED; Hemmerling, A; Huibner, S; Kaul, R; Kulikova, M; Liu, R; Miller, S; Morris, SR; Nagelkerke, N; Newmann, SJ; Reno, H, 2022) |
| "The primary end points were bacterial vaginosis (BV), vaginal candidiasis, trichomoniasis vaginalis (hereafter, "trichomoniasis"), and colonization with Lactobacillus organisms." | 2.73 | Improvement of vaginal health for Kenyan women at risk for acquisition of human immunodeficiency virus type 1: results of a randomized trial. ( Baeten, JM; Chohan, V; Hassan, WM; Holmes, KK; Jaoko, W; Kiarie, J; Kurth, AE; Lavreys, L; Mandaliya, K; McClelland, RS; Ndinya-Achola, JO; Richardson, BA, 2008) |
| "The 11 recurrences were classified as 3 probable reinfections (27%), 2 probable infections from a new sexual partner (18%), and 6 probable treatment failures (55%); 2 of the 6 patients who experienced probable treatment failure had isolates with mild resistance to metronidazole." | 2.73 | Early repeated infections with Trichomonas vaginalis among HIV-positive and HIV-negative women. ( Clark, RA; Curtin, E; Kissinger, P; Leichliter, JS; Martin, DH; Schmidt, N; Secor, WE, 2008) |
| "Sexually transmitted diseases were reduced: Trichomonas vaginalis (rate ratio, 0." | 2.70 | Randomized trial of presumptive sexually transmitted disease therapy during pregnancy in Rakai, Uganda. ( Abramowsky, C; Gray, RH; Kigozi, G; Meehan, M; Moulton, LH; O'Brien, KL; Quinn, TC; Robb, M; Serwadda, D; Sewankambo, NK; Wabwire-Mangen, F; Wawer, MJ, 2001) |
| "Metronidazole (MTZ) has been the treatment of choice for women for decades, and single dose has been considered the first line of therapy." | 2.52 | Trichomonas vaginalis: a review of epidemiologic, clinical and treatment issues. ( Kissinger, P, 2015) |
| "Prevention and treatment of sexually transmitted infections (STIs) in the sexually active population are the main steps to prevent perinatal infection." | 2.41 | Sexually transmitted infections, adverse pregnancy outcome and neonatal infection. ( Moodley, P; Sturm, AW, 2000) |
| "Microsporidiosis is recognized as an increasingly important infection, particularly in patients with human immunodeficiency virus (HIV) infection." | 2.40 | Microsporidial disease in HIV-infected patients: a report of 42 patients and review of the literature. ( Crowe, SM; Leder, K; Ryan, N; Spelman, D, 1998) |
| "Both factors are modulated by bacterial vaginosis (BV) and, to some extent, by Lactobacillus iners, the genital Lactobacillus spp." | 1.51 | Impact of Standard Bacterial Vaginosis Treatment on the Genital Microbiota, Immune Milieu, and Ex Vivo Human Immunodeficiency Virus Susceptibility. ( Anzala, O; Dizzell, S; Gajer, P; Huibner, S; Humphrys, M; Joag, V; Kaul, R; Kaushic, C; Kimani, J; Mureithi, M; Obila, O; Oyugi, J; Ravel, J; Scott, MC; Shahabi, K; Shannon, B; Tharao, W, 2019) |
| "Only few cases of noma infection in adults have been described." | 1.46 | Noma in an HIV infected patient in Guinea-Bissau: a case report. ( Hønge, BL; Jespersen, S; Madsen, T; Medina, C; Wejse, C, 2017) |
| " The objective of this animal study was to determine whether pre-treatment with antibiotics affects the intestinal bioavailability of Atazanavir (ATV) and Ritonavir (RTV)." | 1.40 | Metronidazole or Cotrimoxazole therapy is associated with a decrease in intestinal bioavailability of common antiretroviral drugs. ( Desjeux, JF; Dossou-Yovo, F; Eto, B; Limas-Nzouzi, N; Mamadou, G; Miantezila, J; Soudy, ID, 2014) |
| "Metronidazole treatment reduced the microbial diversity and perturbed the BV-associated microbiota, but rarely resulted in the establishment of a lactobacilli-dominated microbiota." | 1.36 | Deep sequencing of the vaginal microbiota of women with HIV. ( Changalucha, J; Dickson, RJ; Fernandes, AD; Gloor, GB; Hummelen, R; Macklaim, JM; Reid, G, 2010) |
| "Amebic liver abscess is an emerging parasitic disease in human immunodeficiency virus (HIV)-infected patients." | 1.35 | Comparison of clinical characteristics of amebic liver abscess in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. ( Chen, JK; Chen, KM; Chen, YJ; Chen, YS; Lee, SS; Liu, YC; Mai, MH; Sy, CL; Tsai, HC; Wang, YH; Wann, SR; Wu, KS, 2008) |
| "Although infrequent, metastatic Crohn's disease should be suspected in cases of recalcitrant ulcerative conditions, even in the absence of intestinal disease." | 1.33 | Metastatic Crohn's disease mimicking genital pyoderma gangrenosum in an HIV patient. ( Avilés-Izquierdo, JA; Lázaro-Ochaita, P; Longo-Imedio, I; Suárez-Fernández, R, 2005) |
| "As part of a larger program to control STDs, incorporating metronidazole to treat male trichomoniasis could represent a cost-effective means to reduce HIV transmission in this high-risk group." | 1.33 | The cost-effectiveness of treating male trichomoniasis to avert HIV transmission in men seeking sexually transmitted disease care in Malawi. ( Behets, F; Chilongozi, D; Cohen, MS; Dow, WH; Martinson, FE; Miller, WC; Price, MA; Stewart, SR, 2006) |
| "Research on the relationship between sexually transmitted diseases (STDs) and HIV was presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)." | 1.30 | Data on HIV infection in women expands. ( Eagan, L, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.32) | 18.7374 |
| 1990's | 10 (13.16) | 18.2507 |
| 2000's | 35 (46.05) | 29.6817 |
| 2010's | 22 (28.95) | 24.3611 |
| 2020's | 8 (10.53) | 2.80 |
| Authors | Studies |
|---|---|
| Armstrong, E | 2 |
| Hemmerling, A | 2 |
| Miller, S | 2 |
| Burke, KE | 2 |
| Newmann, SJ | 2 |
| Morris, SR | 2 |
| Reno, H | 2 |
| Huibner, S | 4 |
| Kulikova, M | 2 |
| Liu, R | 1 |
| Crawford, ED | 1 |
| Castañeda, GR | 1 |
| Nagelkerke, N | 2 |
| Coburn, B | 2 |
| Cohen, CR | 3 |
| Kaul, R | 5 |
| Cenkowski, M | 1 |
| Wudel, B | 1 |
| Poliquin, V | 1 |
| Kissinger, PJ | 1 |
| Gaydos, CA | 2 |
| Seña, AC | 1 |
| Scott McClelland, R | 1 |
| Soper, D | 1 |
| Secor, WE | 2 |
| Legendre, D | 1 |
| Workowski, KA | 1 |
| Muzny, CA | 1 |
| Bangar, S | 1 |
| Sonar, P | 1 |
| Mane, A | 1 |
| Sane, S | 1 |
| Kadam, A | 1 |
| Katendra, TL | 1 |
| Rahane, G | 1 |
| Sinha, A | 1 |
| Sahay, S | 1 |
| Zhao, X | 1 |
| Boyd, P | 1 |
| Bashi, YD | 1 |
| Murphy, DJ | 1 |
| McCoy, CF | 1 |
| Coulter, S | 1 |
| Laverty, G | 1 |
| Malcolm, RK | 1 |
| Valencia, ME | 1 |
| Montejano, R | 1 |
| Moreno, V | 1 |
| Martín Carbonero, L | 1 |
| Bernardino, JI | 1 |
| Serrano, L | 1 |
| Nkuize, M | 1 |
| Vanderpas, J | 1 |
| Buset, M | 1 |
| Gomez-Galdon, M | 1 |
| Delforge, M | 1 |
| Miendje-Deyi, VY | 1 |
| Muls, V | 1 |
| De Wit, S | 1 |
| Hatcher, J | 1 |
| Williamson, L | 1 |
| Madsen, T | 1 |
| Medina, C | 1 |
| Jespersen, S | 1 |
| Wejse, C | 1 |
| Hønge, BL | 1 |
| Sherley, M | 1 |
| Martin, SJ | 1 |
| Joag, V | 2 |
| Obila, O | 1 |
| Gajer, P | 1 |
| Scott, MC | 1 |
| Dizzell, S | 1 |
| Humphrys, M | 1 |
| Shahabi, K | 1 |
| Shannon, B | 1 |
| Tharao, W | 1 |
| Mureithi, M | 1 |
| Oyugi, J | 1 |
| Kimani, J | 1 |
| Kaushic, C | 1 |
| Ravel, J | 1 |
| Anzala, O | 1 |
| Vipani, A | 1 |
| Yang, MX | 1 |
| Galiwango, RM | 1 |
| Bagaya, B | 1 |
| Mpendo, J | 1 |
| Okech, B | 1 |
| Nanvubya, A | 1 |
| Ssetaala, A | 1 |
| Muwanga, M | 1 |
| Balkus, JE | 1 |
| Richardson, BA | 3 |
| Mochache, V | 1 |
| Chohan, V | 2 |
| Chan, JD | 1 |
| Masese, L | 1 |
| Shafi, J | 1 |
| Marrazzo, J | 1 |
| Farquhar, C | 1 |
| McClelland, RS | 4 |
| Kissinger, P | 6 |
| Adamski, A | 1 |
| Clark, RA | 5 |
| Mena, L | 3 |
| Levison, J | 3 |
| Martin, DH | 5 |
| Dossou-Yovo, F | 1 |
| Mamadou, G | 1 |
| Soudy, ID | 1 |
| Limas-Nzouzi, N | 1 |
| Miantezila, J | 1 |
| Desjeux, JF | 1 |
| Eto, B | 1 |
| Azodo, CC | 1 |
| Ojehanon, PI | 1 |
| Warren, S | 1 |
| Freedman, A | 1 |
| Lomax, N | 1 |
| Christian, A | 1 |
| Pérez-Chacón, G | 1 |
| Pocaterra, LA | 1 |
| Rojas, E | 1 |
| Hernán, A | 1 |
| Jiménez, JC | 1 |
| Núñez, L | 1 |
| Milánkovits, M | 1 |
| Rebbapragada, A | 1 |
| Howe, K | 1 |
| Wachihi, C | 1 |
| Pettengell, C | 1 |
| Sunderji, S | 1 |
| Ball, TB | 1 |
| Plummer, FA | 1 |
| Jaoko, W | 3 |
| Amedee, A | 1 |
| Dumestre, J | 1 |
| Theall, KP | 1 |
| Myers, L | 2 |
| Hagensee, ME | 1 |
| Farley, TA | 1 |
| Barakat, SS | 1 |
| Campbell, WN | 1 |
| Wu, KS | 1 |
| Tsai, HC | 1 |
| Lee, SS | 1 |
| Liu, YC | 1 |
| Wann, SR | 1 |
| Wang, YH | 1 |
| Mai, MH | 1 |
| Chen, JK | 1 |
| Sy, CL | 1 |
| Chen, KM | 1 |
| Chen, YJ | 1 |
| Chen, YS | 1 |
| Taulo, F | 1 |
| Berry, M | 1 |
| Tsui, A | 1 |
| Makanani, B | 1 |
| Kafulafula, G | 2 |
| Li, Q | 1 |
| Nkhoma, C | 1 |
| Kumwenda, JJ | 1 |
| Kumwenda, N | 1 |
| Taha, TE | 2 |
| Gutiérrez-Cisneros, MJ | 1 |
| Martín-Rabadán, P | 1 |
| Menchén, L | 1 |
| García-Lechuz, JM | 2 |
| Fuentes, I | 1 |
| Gárate, T | 1 |
| Bouza, E | 2 |
| Moreira, C | 1 |
| Venkatesh, KK | 1 |
| DeLong, A | 1 |
| Liu, T | 1 |
| Kurpewski, J | 1 |
| Ingersoll, J | 1 |
| Caliendo, AM | 1 |
| Cu-Uvin, S | 2 |
| ter Avest, E | 1 |
| Uyttenboogaart, M | 1 |
| Dorgelo, J | 1 |
| ter Maaten, JC | 1 |
| Gatski, M | 2 |
| Henderson, H | 2 |
| Schmidt, N | 3 |
| Rosenthal, SL | 2 |
| Idris, NS | 1 |
| Dwipoerwantoro, PG | 1 |
| Kurniawan, A | 1 |
| Said, M | 1 |
| Hummelen, R | 2 |
| Fernandes, AD | 1 |
| Macklaim, JM | 1 |
| Dickson, RJ | 1 |
| Changalucha, J | 2 |
| Gloor, GB | 1 |
| Reid, G | 2 |
| Butamanya, NL | 1 |
| Cook, A | 1 |
| Habbema, JD | 1 |
| Phiri, R | 1 |
| Feller, L | 2 |
| Blignaut, E | 2 |
| Le Falher, G | 1 |
| Makinson, A | 1 |
| Eden, A | 1 |
| Lesnik, A | 1 |
| Le Moing, V | 1 |
| Reynes, J | 1 |
| Masese, LN | 1 |
| Graham, SM | 1 |
| Gitau, R | 1 |
| Peshu, N | 1 |
| Ndinya-Achola, JO | 2 |
| Mandaliya, K | 3 |
| Overbaugh, J | 2 |
| Coleman, JS | 1 |
| Witter, F | 1 |
| Moodley, P | 2 |
| Wilkinson, D | 1 |
| Connolly, C | 1 |
| Sturm, AW | 2 |
| Price, MA | 3 |
| Zimba, D | 1 |
| Hoffman, IF | 2 |
| Kaydos-Daniels, SC | 2 |
| Miller, WC | 3 |
| Martinson, F | 3 |
| Chilongozi, D | 3 |
| Kip, E | 1 |
| Msowoya, E | 1 |
| Hobbs, MM | 2 |
| Kazembe, P | 1 |
| Cohen, MS | 4 |
| Harwell, JI | 1 |
| Moench, T | 1 |
| Mayer, KH | 1 |
| Chapman, S | 1 |
| Rodriguez, I | 1 |
| Mwachari, CW | 1 |
| Meier, AS | 1 |
| Muyodi, J | 1 |
| Gatei, W | 1 |
| Waiyaki, P | 1 |
| Hoffman, I | 2 |
| Namakwha, D | 1 |
| Gama, S | 2 |
| Phakati, S | 1 |
| Shangase, L | 1 |
| Avilés-Izquierdo, JA | 1 |
| Suárez-Fernández, R | 1 |
| Lázaro-Ochaita, P | 1 |
| Longo-Imedio, I | 1 |
| Brown, ER | 1 |
| Fawzi, W | 1 |
| Read, JS | 1 |
| Sinkala, M | 1 |
| Martinson, FE | 2 |
| Msamanga, G | 1 |
| Emel, L | 1 |
| Adeniyi-Jones, S | 1 |
| Goldenberg, R | 1 |
| Stewart, SR | 1 |
| Behets, F | 1 |
| Dow, WH | 1 |
| Brindicci, G | 1 |
| Picciarelli, C | 1 |
| Fumarola, L | 1 |
| Carbonara, S | 1 |
| Stano, F | 1 |
| Ciracì, E | 1 |
| Gramiccia, M | 1 |
| Sannella, AR | 1 |
| Milella, M | 1 |
| De Vito, D | 1 |
| Monno, R | 1 |
| Monno, L | 1 |
| Myer, L | 1 |
| Kuhn, L | 1 |
| Denny, L | 1 |
| Wright, TC | 1 |
| Hosseinipour, MC | 1 |
| Napravnik, S | 1 |
| Joaki, G | 1 |
| Mbeye, N | 1 |
| Banda, B | 1 |
| Loulergue, P | 1 |
| Mir, O | 1 |
| Hsu, MS | 1 |
| Hsieh, SM | 1 |
| Chen, MY | 1 |
| Hung, CC | 1 |
| Chang, SC | 1 |
| Hassan, WM | 1 |
| Lavreys, L | 1 |
| Kiarie, J | 1 |
| Baeten, JM | 1 |
| Kurth, AE | 1 |
| Holmes, KK | 1 |
| Leichliter, JS | 1 |
| Curtin, E | 1 |
| Laing, RB | 1 |
| Wynn, RF | 1 |
| Leen, CL | 1 |
| Stansfield, R | 1 |
| Ebrahimzadeh, A | 1 |
| Bottone, EJ | 1 |
| Fontana, M | 1 |
| Zuin, G | 1 |
| Massironi, E | 1 |
| Bastoni, K | 1 |
| Altamura, N | 1 |
| Principi, N | 1 |
| Leder, K | 1 |
| Ryan, N | 1 |
| Spelman, D | 1 |
| Crowe, SM | 1 |
| Simpson-Dent, S | 1 |
| Fearfield, LA | 1 |
| Staughton, RC | 1 |
| Hänsel, A | 1 |
| Schmid, G | 1 |
| Markowitz, L | 1 |
| Joesoef, R | 1 |
| Koumans, E | 1 |
| Wang, CC | 1 |
| Reilly, M | 1 |
| Emery, SR | 1 |
| Chohan, B | 1 |
| Ndinya-Achola, J | 1 |
| Bwayo, J | 1 |
| Kreiss, JK | 1 |
| Hanna, L | 1 |
| Eagan, L | 1 |
| Simoes, JA | 1 |
| Hashemi, FB | 1 |
| Aroutcheva, AA | 1 |
| Heimler, I | 1 |
| Spear, GT | 1 |
| Shott, S | 1 |
| Faro, S | 1 |
| Yar'mov, N | 1 |
| Gachev, N | 1 |
| Petkov, K | 1 |
| Ghayoumi, N | 1 |
| Gray, RH | 1 |
| Wabwire-Mangen, F | 1 |
| Kigozi, G | 1 |
| Sewankambo, NK | 1 |
| Serwadda, D | 1 |
| Moulton, LH | 1 |
| Quinn, TC | 1 |
| O'Brien, KL | 1 |
| Meehan, M | 1 |
| Abramowsky, C | 1 |
| Robb, M | 1 |
| Wawer, MJ | 1 |
| Mank, TG | 1 |
| Zaat, JO | 1 |
| Peláez, T | 1 |
| Alcalá, L | 1 |
| Alonso, R | 1 |
| Rodríguez-Créixems, M | 1 |
| Bianco, R | 1 |
| Bañuls, J | 1 |
| Ramon, D | 1 |
| Aniz, E | 1 |
| Jorda, E | 1 |
| Torres, V | 1 |
| Winkler, JR | 1 |
| Murray, PA | 1 |
| Grassi, M | 1 |
| Hammerle, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II-b Randomized Double-Blind Placebo-Controlled Trial of Lactobacillus Crispatus CTV-05 (LACTIN-V) to Prevent the Recurrence of Bacterial Vaginosis[NCT02766023] | Phase 2 | 228 participants (Actual) | Interventional | 2016-06-03 | Completed | ||
| Testing the Ability of a Microbiome - Focused Intervention to Reduce HIV Susceptibility in Ugandan Men[NCT03412071] | 125 participants (Anticipated) | Interventional | 2017-12-07 | Recruiting | |||
| Trichomonas Vaginalis Repeat Infections Among HIV Negative Women[NCT01832480] | Phase 3 | 623 participants (Actual) | Interventional | 2014-10-06 | Completed | ||
| e-SiHLE: An Internet Pregnancy Prevention for Older Teenage Girls[NCT01579617] | 637 participants (Actual) | Interventional | 2012-08-31 | Completed | |||
| The Effect of Probiotic Supplementation With Lactobacillus GR-1 and RC-14,on the Immune Status, Diarrhea and Bacterial Vaginosis Cure Rate Among HIV Patients; a Randomised, Placebo Controlled Trial[NCT00536848] | Phase 2/Phase 3 | 65 participants (Actual) | Interventional | 2007-10-31 | Active, not recruiting | ||
| Randomized Phase IV Trial of Metronidazole Single Dose Versus 7 Day Dose for Treatment of Trichomonas Vaginalis Among HIV-infected Women[NCT01018095] | Phase 4 | 270 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| A Phase IIa Study of the Colonization Efficiency, Safety and Acceptability of LACTIN-V Administered Vaginally to Women With Bacterial Vaginosis[NCT00635622] | Phase 2 | 40 participants (Anticipated) | Interventional | 2008-04-30 | Completed | ||
| A Phase I Study of the Safety of LACTIN-V Administered Vaginally to Healthy Women[NCT00537576] | Phase 1 | 12 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Tolerability of LACTIN-V and the applicator was measured by the proportion of participants who discontinued the study product prior to completing the dose schedule due to an adverse event. (NCT02766023)
Timeframe: Day 1 to Day 84
| Intervention | Participants (Count of Participants) |
|---|---|
| LACTIN-V | 1 |
| Placebo | 0 |
Colonization of L. crispatus was determined from the concentrations of L. crispatus species and L. crispatus CTV-05 obtained from qPCR. Successful colonization was defined as: If CTV-05 concentration was above the lower limit of detection (LLOD) and the L. crispatus was above the LLOD, then successful colonization had occurred. If either CTV-05 or L. crispatus concentration was below LLOD or indeterminate, then successful colonization had not occurred. The LLOD for CTV-05 was 660 copies/mL and the LLOD for L. crispatus was 953 copies/mL (NCT02766023)
Timeframe: Day 1 to Day 84
| Intervention | percentage of participants (Number) |
|---|---|
| LACTIN-V | 0.85 |
| Placebo | 0.07 |
Colonization of L. crispatus was determined from the concentrations of L. crispatus species and L. crispatus CTV-05 obtained from qPCR. Successful colonization was defined as: If CTV-05 concentration was above the lower limit of detection (LLOD) and the L. crispatus was above the LLOD, then successful colonization had occurred. If either CTV-05 or L. crispatus concentration was below LLOD or indeterminate, then successful colonization had not occurred. The LLOD for CTV-05 was 660 copies/mL and the LLOD for L. crispatus was 953 copies/mL (NCT02766023)
Timeframe: Day 1 to Day 168
| Intervention | percentage of participants (Number) |
|---|---|
| LACTIN-V | 0.86 |
| Placebo | 0.08 |
"Adverse events and serious adverse events were collected during the entire study period. Relatedness to study product was assessed by the site investigator according to the protocol definition of related as There is a reasonable possibility that the study product caused the AE. Reasonable possibility means that there is evidence to suggest a causal relationship between the study product and the AE." (NCT02766023)
Timeframe: Day 1 to Day 168
| Intervention | proportion of participants (Number) |
|---|---|
| LACTIN-V | 0.11 |
| Placebo | 0.07 |
A positive BV diagnosis was defined by at least 3 of the 4 Amsel criteria and a Nugent score of 4-10. Amsel criteria are: homogeneous, thin, grayish-white discharge that smoothly coats the vaginal walls; vaginal pH >4.5; positive whiff-amine test, defined as the presence of a fishy odor when a drop of 10% potassium hydroxide is added to a sample of vaginal discharge; and presence of clue cells (>20%) on microscopy. The Nugent score is calculated by assessing for the presence of large Gram-positive rods scored as 0 to 4, small Gram-variable rods scored as 0 to 4, and curved Gram-variable rods scored as 0 to 2. All BV diagnoses following 15 days after enrollment (22 days after commencement of MetroGel treatment) were considered a recurrent episode. (NCT02766023)
Timeframe: Day 1 to Day 168
| Intervention | percentage of participants (Number) |
|---|---|
| LACTIN-V | 0.39 |
| Placebo | 0.54 |
A positive BV diagnosis was defined by meeting at least 3 of the 4 Amsel criteria and a Nugent score of 4-10. Amsel criteria are: homogeneous, thin, grayish-white discharge that smoothly coats the vaginal walls; vaginal pH >4.5; positive whiff-amine test, defined as the presence of a fishy odor when a drop of 10% potassium hydroxide is added to a sample of vaginal discharge; and presence of clue cells (>20%) on microscopy. The Amsel score ranges from 0-4, where higher scores mean a worse outcome. The Nugent score is calculated by assessing for the presence of large Gram-positive rods scored as 0 to 4, small Gram-variable rods scored as 0 to 4, and curved Gram-variable rods scored as 0 to 2, and adding all component scores. The Nugent score ranges from 0-10, where higher scores mean a worse outcome. All BV diagnoses following 15 days after enrollment (22 days after commencement of MetroGel treatment) were considered a recurrent episode. (NCT02766023)
Timeframe: Day 1 to Day 84
| Intervention | proportion of participants (Number) |
|---|---|
| LACTIN-V | 0.30 |
| Placebo | 0.45 |
"Participants answered a detailed self-administered questionnaire at Week 12 assessing the acceptability of the study product and the applicator. Questionnaire items included rating aspects of the product and applicator by various measures, including by rating factors on a 0-10 scale, with 0 being not at all and 10 being extremely." (NCT02766023)
Timeframe: Day 84
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Effectiveness | Comfort | Ease of use | Vaginal health | Other Finding | |
| LACTIN-V | 7.53 | 8.16 | 8.99 | 7.37 | 8.21 |
| Placebo | 6.72 | 8.07 | 8.75 | 7.01 | 9.27 |
"Participants answered a detailed self-administered questionnaire at Week 12 assessing the acceptability of the study product and the applicator. Questionnaire items included rating aspects of the product and applicator by various measures, including by rating factors on use of the product on a 0-10 scale, with 0 being not at all and 10 being extremely so." (NCT02766023)
Timeframe: Day 84
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| High frequency | Vaginal Dryness | Discomfort | Messiness | Disapproval | Other issue | |
| LACTIN-V | 2.97 | 1.71 | 1.53 | 2.10 | 0.98 | 7.08 |
| Placebo | 2.63 | 1.37 | 1.01 | 1.68 | 0.79 | 7.62 |
Colonization of L. crispatus was determined from the concentrations of L. crispatus species and L. crispatus CTV-05 obtained from qPCR. Successful colonization was defined as: If CTV-05 concentration was above the lower limit of detection (LLOD) and the L. crispatus was above the LLOD, then successful colonization had occurred. If either CTV-05 or L. crispatus concentration was below LLOD or indeterminate, then successful colonization had not occurred. The LLOD for CTV-05 was 660 copies/mL and the LLOD for L. crispatus was 953 copies/mL (NCT02766023)
Timeframe: Day 1
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Condom-less sex acts since last visit | No condom-less sex acts since last visit | |
| LACTIN-V | 0 | 4 |
| Placebo | 0 | 0 |
Colonization of L. crispatus was determined from the concentrations of L. crispatus species and L. crispatus CTV-05 obtained from qPCR. Successful colonization was defined as: If CTV-05 concentration was above the lower limit of detection (LLOD) and the L. crispatus was above the LLOD, then successful colonization had occurred. If either CTV-05 or L. crispatus concentration was below LLOD or indeterminate, then successful colonization had not occurred. The LLOD for CTV-05 was 660 copies/mL and the LLOD for L. crispatus was 953 copies/mL (NCT02766023)
Timeframe: Day 28
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Condom-less sex acts since last visit | No condom-less sex acts since last visit | |
| LACTIN-V | 37 | 76 |
| Placebo | 1 | 3 |
Colonization of L. crispatus was determined from the concentrations of L. crispatus species and L. crispatus CTV-05 obtained from qPCR. Successful colonization was defined as: If CTV-05 concentration was above the lower limit of detection (LLOD) and the L. crispatus was above the LLOD, then successful colonization had occurred. If either CTV-05 or L. crispatus concentration was below LLOD or indeterminate, then successful colonization had not occurred. The LLOD for CTV-05 was 660 copies/mL and the LLOD for L. crispatus was 953 copies/mL (NCT02766023)
Timeframe: Day 56
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Condom-less sex acts since last visit | No condom-less sex acts since last visit | |
| LACTIN-V | 28 | 78 |
| Placebo | 0 | 1 |
Colonization of L. crispatus was determined from the concentrations of L. crispatus species and L. crispatus CTV-05 obtained from qPCR. Successful colonization was defined as: If CTV-05 concentration was above the lower limit of detection (LLOD) and the L. crispatus was above the LLOD, then successful colonization had occurred. If either CTV-05 or L. crispatus concentration was below LLOD or indeterminate, then successful colonization had not occurred. The LLOD for CTV-05 was 660 copies/mL and the LLOD for L. crispatus was 953 copies/mL (NCT02766023)
Timeframe: Day 84
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Condom-less sex acts since last visit | No condom-less sex acts since last visit | |
| LACTIN-V | 38 | 64 |
| Placebo | 0 | 2 |
Colonization of L. crispatus was determined from the concentrations of L. crispatus species and L. crispatus CTV-05 obtained from qPCR. Successful colonization was defined as: If CTV-05 concentration was above the lower limit of detection (LLOD) and the L. crispatus was above the LLOD, then successful colonization had occurred. If either CTV-05 or L. crispatus concentration was below LLOD or indeterminate, then successful colonization had not occurred. The LLOD for CTV-05 was 660 copies/mL and the LLOD for L. crispatus was 953 copies/mL (NCT02766023)
Timeframe: Day 28
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Menses since last visit | No menses since last visit | |
| LACTIN-V | 93 | 20 |
| Placebo | 3 | 1 |
Colonization of L. crispatus was determined from the concentrations of L. crispatus species and L. crispatus CTV-05 obtained from qPCR. Successful colonization was defined as: If CTV-05 concentration was above the lower limit of detection (LLOD) and the L. crispatus was above the LLOD, then successful colonization had occurred. If either CTV-05 or L. crispatus concentration was below LLOD or indeterminate, then successful colonization had not occurred. The LLOD for CTV-05 was 660 copies/mL and the LLOD for L. crispatus was 953 copies/mL (NCT02766023)
Timeframe: Day 56
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Menses since last visit | No menses since last visit | |
| LACTIN-V | 76 | 30 |
| Placebo | 1 | 0 |
Colonization of L. crispatus was determined from the concentrations of L. crispatus species and L. crispatus CTV-05 obtained from qPCR. Successful colonization was defined as: If CTV-05 concentration was above the lower limit of detection (LLOD) and the L. crispatus was above the LLOD, then successful colonization had occurred. If either CTV-05 or L. crispatus concentration was below LLOD or indeterminate, then successful colonization had not occurred. The LLOD for CTV-05 was 660 copies/mL and the LLOD for L. crispatus was 953 copies/mL (NCT02766023)
Timeframe: Day 84
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Menses since last visit | No menses since last visit | |
| LACTIN-V | 74 | 28 |
| Placebo | 2 | 0 |
A subject was considered compliant with the assigned study product if she took 4 of the first 5 daily doses and at least 75% of the scheduled doses overall prior to the first diagnosis of BV or through Week 12, whichever occurred first. Compliance was assessed by subject report via the memory aid and, separately, applicator staining of the returned kit. Compliance was assessed on a weekly basis and the time (week) at which the subject became non-compliant was determined by blinded PI review. (NCT02766023)
Timeframe: Day 1 to Day 84
| Intervention | proportion of participants (Number) | |
|---|---|---|
| Self-report | Staining | |
| LACTIN-V | 0.80 | 0.77 |
| Placebo | 0.78 | 0.72 |
Participants answered a detailed self-administered questionnaire at Week 12 assessing the acceptability of the study product and the applicator. Questionnaire items included rating aspects of the product and applicator by Likert-scale responses of strongly agree, agree, neutral, disagree and strongly disagree. (NCT02766023)
Timeframe: Day 84
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| I was satisfied overall with vaginal applicator72598130 | I was satisfied overall with vaginal applicator72598131 | Satisfied with comfort of vaginal applicator72598130 | Satisfied with comfort of vaginal applicator72598131 | Satisfied with ease of use of vaginal applicator72598130 | Satisfied with ease of use of vaginal applicator72598131 | Vaginal health improved with study participation72598131 | Vaginal health improved with study participation72598130 | Important I use product without partner knowing72598130 | Important I use product without partner knowing72598131 | Important for me that partner approved of product72598130 | Important for me that partner approved of product72598131 | I would use the product again72598131 | I would use the product again72598130 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Strongly agree | Agree | Neutral | Disagree | Strongly disagree | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 59 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 22 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 30 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 55 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 56 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 32 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 17 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 63 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 31 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 58 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 8 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 46 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 18 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 25 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 21 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 32 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 29 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 15 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 45 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 15 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 8 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 9 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 22 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 23 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 34 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 13 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 30 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 11 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 72 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 28 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 39 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 24 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 11 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Presence of TV is assessed by nucleic acid amplification test (NAAT) of vaginal swab collected 4 weeks post treatment completion. (NCT01832480)
Timeframe: 4 weeks post treatment completion
| Intervention | Participants (Count of Participants) |
|---|---|
| Trichomonas (TV) Positive After 2 g Dose | 58 |
| Trichomonas (TV) Positive After Metronidazole (MTZ) Multi Dose | 34 |
At the participants' test of cure (TOC) visits they were screened for Trichomonas vaginalis using (InPouch) culture. Presence of parasite will yield a culture positive result. (NCT01018095)
Timeframe: test-of-cure visit at 6-12 days post-treatment completion
| Intervention | participants (Number) |
|---|---|
| 7 Day Dose | 11 |
| Single Dose | 21 |
Participants who returned for their follow up visits were tested for Trichomonas vaginalis using InPouch culture. If parasites are present, it will yield a culture positive result. (NCT01018095)
Timeframe: 3 months post-enrollment
| Intervention | participants (Number) |
|---|---|
| 7 Day Dose | 8 |
| Single Dose | 19 |
"Acceptability and overall satisfaction with the study product was measured using the response to the following question: I would use the product again with the following response options (strongly agree, agree, neutral, disagree, strongly disagree)~Acceptability is reported as the number of women in each group who strongly agreed or agreed with the statement that they would use the product again." (NCT00537576)
Timeframe: 35 days
| Intervention | participants (Number) |
|---|---|
| Low Dose Applicator | 3 |
| Medium Dose Applicator | 3 |
| High Dose Applicator | 2 |
| Placebo Control Substance Low Dose | 1 |
| Placebo Control Substance Medium Dose | 0 |
| Placebo Control Substance High Dose | 1 |
Safety was measured by comparing the number of women experiencing adverse events of grade 3 or higher during the study. (NCT00537576)
Timeframe: 35 days
| Intervention | participants (Number) |
|---|---|
| Low Dose Applicator | 0 |
| Medium Dose Applicator | 0 |
| High Dose Applicator | 0 |
| Placebo Control Substance Low Dose | 0 |
| Placebo Control Substance Medium Dose | 0 |
| Placebo Control Substance High Dose | 0 |
Tolerability was measured as proportion of women remaining in the study, and NOT prematurely exiting the trial due to an adverse event. (NCT00537576)
Timeframe: 35 days
| Intervention | participants (Number) |
|---|---|
| Low Dose Applicator | 3 |
| Medium Dose Applicator | 3 |
| High Dose Applicator | 3 |
| Placebo Control Substance Low Dose | 1 |
| Placebo Control Substance Medium Dose | 1 |
| Placebo Control Substance High Dose | 1 |
8 reviews available for metronidazole and HIV Coinfection
| Article | Year |
|---|---|
Trichomonas vaginalis: a review of epidemiologic, clinical and treatment issues.
Topics: Drug Resistance; Female; Herpes Genitalis; HIV Infections; Humans; Metronidazole; Recurrence; Treatm | 2015 |
[Autochthonous amebic liver abscess in Spain: an emerging disease? Case report and description of a PCR-based diagnostic test].
Topics: Adult; Aged; Amebicides; Animals; Antibodies, Protozoan; Chloroquine; Combined Modality Therapy; Com | 2009 |
Trichomonas vaginalis vaginitis in obstetrics and gynecology practice: new concepts and controversies.
Topics: Anti-Infective Agents; Coinfection; Directive Counseling; Female; HIV Infections; Humans; Metronidaz | 2013 |
Microsporidial disease in HIV-infected patients: a report of 42 patients and review of the literature.
Topics: Adult; Aged; Albendazole; Animals; Anti-Infective Agents; Antiprotozoal Agents; Apansporoblastina; E | 1998 |
Sexually transmitted infections, adverse pregnancy outcome and neonatal infection.
Topics: Diagnosis, Differential; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmi | 2000 |
The use of metronidazole in the treatment of periodontal diseases.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Gingivitis, Necrotizing Ulcerative; HIV Infections; Huma | 2001 |
Diagnostic advantages and therapeutic options for giardiasis.
Topics: Animals; Antiprotozoal Agents; Female; Giardiasis; HIV Infections; Humans; Metronidazole; Pregnancy; | 2001 |
Diagnosis and management of HIV-associated periodontal lesions.
Topics: Chlorhexidine; Dental Care for Disabled; Dental Scaling; Gingivitis; Gingivitis, Necrotizing Ulcerat | 1989 |
17 trials available for metronidazole and HIV Coinfection
| Article | Year |
|---|---|
Metronidazole treatment rapidly reduces genital inflammation through effects on bacterial vaginosis-associated bacteria rather than lactobacilli.
Topics: Bacteria; Female; HIV Infections; Humans; Inflammation; Lactobacillus; Metronidazole; Vagina; Vagino | 2022 |
Diagnosis and Management of Trichomonas vaginalis: Summary of Evidence Reviewed for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines.
Topics: Centers for Disease Control and Prevention, U.S.; Female; HIV Infections; Humans; Infant, Newborn; M | 2022 |
Sustained effect of LACTIN-V (Lactobacillus crispatus CTV-05) on genital immunology following standard bacterial vaginosis treatment: results from a randomised, placebo-controlled trial.
Topics: Bacteria; Cadherins; Canada; Female; HIV Infections; Humans; Inflammation; Lactobacillus crispatus; | 2022 |
Prevention of recurrence of bacterial vaginosis using lactobacilli-containing vaginal tablets among women with HIV: a randomized, placebo-controlled, double-blinded phase IV trial.
Topics: COVID-19; Female; HIV Infections; Humans; India; Lactobacillus; Metronidazole; Pandemics; Treatment | 2023 |
Protocol for a randomized clinical trial exploring the effect of antimicrobial agents on the penile microbiota, immunology and HIV susceptibility of Ugandan men.
Topics: Administration, Cutaneous; Administration, Oral; Anti-Infective Agents; Bacteria; CD4-Positive T-Lym | 2019 |
Fertility intentions of HIV-1 infected and uninfected women in Malawi: a longitudinal study.
Topics: Adult; Anti-Bacterial Agents; Family Planning Services; Female; Fertility; HIV Infections; HIV-1; Hu | 2009 |
Effect of treatment of asymptomatic bacterial vaginosis on HIV-1 shedding in the genital tract among women on antiretroviral therapy: a pilot study.
Topics: Adult; Anti-Infective Agents; Antiretroviral Therapy, Highly Active; Female; Genitalia, Female; HIV | 2009 |
Patient-delivered partner treatment and Trichomonas vaginalis repeat infection among human immunodeficiency virus-infected women.
Topics: Adult; Antiprotozoal Agents; Cohort Studies; Female; HIV Infections; HIV-1; Humans; Male; Medication | 2010 |
Lactobacillus rhamnosus GR-1 and L. reuteri RC-14 to prevent or cure bacterial vaginosis among women with HIV.
Topics: Adolescent; Adult; Anti-Infective Agents; Double-Blind Method; Female; HIV Infections; Humans; Lacti | 2010 |
A randomized treatment trial: single versus 7-day dose of metronidazole for the treatment of Trichomonas vaginalis among HIV-infected women.
Topics: Adult; Antitrichomonal Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Drug Administration | 2010 |
A randomized treatment trial: single versus 7-day dose of metronidazole for the treatment of Trichomonas vaginalis among HIV-infected women.
Topics: Adult; Antitrichomonal Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Drug Administration | 2010 |
A randomized treatment trial: single versus 7-day dose of metronidazole for the treatment of Trichomonas vaginalis among HIV-infected women.
Topics: Adult; Antitrichomonal Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Drug Administration | 2010 |
A randomized treatment trial: single versus 7-day dose of metronidazole for the treatment of Trichomonas vaginalis among HIV-infected women.
Topics: Adult; Antitrichomonal Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Drug Administration | 2010 |
Addition of treatment for trichomoniasis to syndromic management of urethritis in Malawi: a randomized clinical trial.
Topics: Administration, Oral; Adult; Animals; Doxycycline; Drug Therapy, Combination; Gentamicins; HIV; HIV | 2003 |
The use of specimens from various genitourinary sites in men, to detect Trichomonas vaginalis infection.
Topics: Adolescent; Adult; Animals; Antiprotozoal Agents; HIV Infections; Humans; Logistic Models; Longitudi | 2004 |
A phase III clinical trial of antibiotics to reduce chorioamnionitis-related perinatal HIV-1 transmission.
Topics: Adult; Anti-Bacterial Agents; Chorioamnionitis; Developing Countries; Disease-Free Survival; Double- | 2006 |
Improvement of vaginal health for Kenyan women at risk for acquisition of human immunodeficiency virus type 1: results of a randomized trial.
Topics: Adolescent; Adult; Anti-Infective Agents; Antifungal Agents; Candidiasis, Vulvovaginal; Female; Fluc | 2008 |
Early repeated infections with Trichomonas vaginalis among HIV-positive and HIV-negative women.
Topics: Adolescent; Adult; Animals; Female; HIV Infections; Humans; Louisiana; Metronidazole; Parasitic Sens | 2008 |
Early repeated infections with Trichomonas vaginalis among HIV-positive and HIV-negative women.
Topics: Adolescent; Adult; Animals; Female; HIV Infections; Humans; Louisiana; Metronidazole; Parasitic Sens | 2008 |
Early repeated infections with Trichomonas vaginalis among HIV-positive and HIV-negative women.
Topics: Adolescent; Adult; Animals; Female; HIV Infections; Humans; Louisiana; Metronidazole; Parasitic Sens | 2008 |
Early repeated infections with Trichomonas vaginalis among HIV-positive and HIV-negative women.
Topics: Adolescent; Adult; Animals; Female; HIV Infections; Humans; Louisiana; Metronidazole; Parasitic Sens | 2008 |
The effect of treatment of vaginal infections on shedding of human immunodeficiency virus type 1.
Topics: Adult; Anti-Bacterial Agents; Antitrichomonal Agents; Candidiasis; DNA, Viral; Down-Regulation; Fema | 2001 |
Randomized trial of presumptive sexually transmitted disease therapy during pregnancy in Rakai, Uganda.
Topics: Azithromycin; Birth Weight; Cefixime; Drug Therapy, Combination; Endophthalmitis; Female; Folic Acid | 2001 |
51 other studies available for metronidazole and HIV Coinfection
| Article | Year |
|---|---|
Vaginal trichomoniasis.
Topics: Administration, Oral; Anti-Infective Agents; Canada; Drug Resistance; Female; Fetal Membranes, Prema | 2022 |
Two into one does go: Formulation development of a multipurpose combination vaginal ring releasing dapivirine and metronidazole for prevention of HIV infection and treatment of bacterial vaginosis.
Topics: Contraceptive Devices, Female; Female; HIV Infections; Humans; Metronidazole; Vagina; Vaginosis, Bac | 2023 |
[Helicobacter pylori infection in the HIV + population: a comorbidity to think about].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Ulcer Agents; Clarithromycin; Comor | 2020 |
Primary antibiotic resistance of Helicobacter pylori isolates is twofold more frequent in HIV-positive than HIV-negative individuals: A descriptive observational study.
Topics: Adult; Aged; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Female; Helicobacter | 2021 |
Noma in a patient with HIV.
Topics: Adult; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-HIV Agents; Antire | 2017 |
Noma in an HIV infected patient in Guinea-Bissau: a case report.
Topics: Adult; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Diagnosis, Differential | 2017 |
Multiple simultaneous infections in a patient with well-controlled HIV: when Occam's razor fails.
Topics: Acquired Immunodeficiency Syndrome; Aftercare; AIDS-Related Opportunistic Infections; Anti-Retrovira | 2017 |
Impact of Standard Bacterial Vaginosis Treatment on the Genital Microbiota, Immune Milieu, and Ex Vivo Human Immunodeficiency Virus Susceptibility.
Topics: Administration, Oral; Adult; CD4-Positive T-Lymphocytes; Cells, Cultured; Cervix Uteri; Cytokines; D | 2019 |
Intestinal Spirochetosis Masquerading as Inflammatory Bowel Disease.
Topics: Adult; Anemia; Anti-Bacterial Agents; Brachyspira; Delayed Diagnosis; Diagnosis, Differential; Gastr | 2019 |
A prospective cohort study comparing the effect of single-dose 2 g metronidazole on Trichomonas vaginalis infection in HIV-seropositive versus HIV-seronegative women.
Topics: Adult; Anti-HIV Agents; Antiprotozoal Agents; Cohort Studies; Drug Therapy, Combination; Female; HIV | 2013 |
Does Antiretroviral Therapy Interfere With the Treatment of Trichomonas vaginalis Among HIV+ Women?
Topics: Antiprotozoal Agents; Female; HIV Infections; HIV Seropositivity; Humans; Metronidazole; Trichomonas | 2013 |
Metronidazole or Cotrimoxazole therapy is associated with a decrease in intestinal bioavailability of common antiretroviral drugs.
Topics: Administration, Oral; Analysis of Variance; Animals; Anti-Retroviral Agents; Atazanavir Sulfate; Bio | 2014 |
Antibiotics prescription in Nigerian dental healthcare services.
Topics: Acquired Immunodeficiency Syndrome; Amoxicillin; Anaphylaxis; Anti-Bacterial Agents; Antibiotic Prop | 2014 |
Intestinal spirochaetosis causing chronic diarrhoea in a patient with HIV infection.
Topics: Adult; Anti-Infective Agents; Biopsy; Chronic Disease; Colonoscopy; Diarrhea; HIV Infections; Homose | 2017 |
Coinfection with
Topics: Adult; Animals; Anthelmintics; Anti-HIV Agents; Antiprotozoal Agents; Coinfection; Diarrhea; Giardia | 2017 |
[Vaginal infections associated with bacterial vaginosis and periodontal disease--effective diagnostic and therapeutic possibilities].
Topics: Anti-Bacterial Agents; Clindamycin; Congresses as Topic; Drug Therapy, Combination; Female; HIV Infe | 2008 |
Bacterial vaginosis in HIV-infected women induces reversible alterations in the cervical immune environment.
Topics: Anti-Bacterial Agents; CD4 Lymphocyte Count; Cervix Uteri; Chemokine CCL5; Female; HIV Infections; H | 2008 |
Trichomonas vaginalis treatment reduces vaginal HIV-1 shedding.
Topics: Adult; Animals; Antiprotozoal Agents; Female; HIV Infections; HIV-1; Humans; Metronidazole; New Orle | 2009 |
Trichomonas vaginalis treatment reduces vaginal HIV-1 shedding.
Topics: Adult; Animals; Antiprotozoal Agents; Female; HIV Infections; HIV-1; Humans; Metronidazole; New Orle | 2009 |
Trichomonas vaginalis treatment reduces vaginal HIV-1 shedding.
Topics: Adult; Animals; Antiprotozoal Agents; Female; HIV Infections; HIV-1; Humans; Metronidazole; New Orle | 2009 |
Trichomonas vaginalis treatment reduces vaginal HIV-1 shedding.
Topics: Adult; Animals; Antiprotozoal Agents; Female; HIV Infections; HIV-1; Humans; Metronidazole; New Orle | 2009 |
Refractory diarrhea in a patient with HIV infection.
Topics: Adult; Anti-Bacterial Agents; Antiretroviral Therapy, Highly Active; Brachyspira; Colon; Diarrhea; G | 2009 |
Comparison of clinical characteristics of amebic liver abscess in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients.
Topics: Adult; Aged; Amebicides; Animals; Entamoeba histolytica; Female; Hemagglutination Tests; HIV Infecti | 2008 |
A patient with neck pain and fever. Combined prevertebral and intraspinal abscess in a patient with a de novo HIV infection.
Topics: Adult; Anti-Bacterial Agents; Ceftriaxone; Cervical Vertebrae; Epidural Abscess; Fever; HIV Infectio | 2009 |
Intestinal parasitic infection of immunocompromised children with diarrhoea: clinical profile and therapeutic response.
Topics: Blastocystis hominis; Child; Child, Preschool; Cross-Sectional Studies; Cryptosporidium; Diarrhea; F | 2010 |
Deep sequencing of the vaginal microbiota of women with HIV.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Female; Gardnerella vaginalis; HIV Infections; Humans; Hyd | 2010 |
The severity, extent and recurrence of necrotizing periodontal disease in relation to HIV status and CD4+ T cell count.
Topics: Adolescent; Adult; Anti-Infective Agents; Anti-Infective Agents, Local; CD4 Lymphocyte Count; Child; | 2010 |
[Two cases of pulmonary gangrene in HIV-infected patients: favorable outcome without surgery].
Topics: Acetamides; Adult; Alcoholism; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Gangre | 2011 |
A prospective study of vaginal trichomoniasis and HIV-1 shedding in women on antiretroviral therapy.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiprotozoal Agents; Antiretroviral Therapy, Highly Active; Coh | 2011 |
Influence of HIV-1 coinfection on effective management of abnormal vaginal discharge.
Topics: Adolescent; Adult; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Chlamydia trachomatis; Cip | 2003 |
A pilot study of treatment of bacterial vaginosis with a buffering vaginal microbicide.
Topics: Acrylic Resins; Administration, Intravaginal; Adult; Anti-Infective Agents, Local; Dose-Response Rel | 2003 |
Chronic diarrhoea in HIV-1-infected adults in Nairobi, Kenya: evaluation of risk factors and the WHO treatment algorithm.
Topics: Adult; Algorithms; Anti-Infective Agents; Chronic Disease; Cohort Studies; Diarrhea; Drug Therapy, C | 2003 |
Vaginal ring may help with HIV prevention.
Topics: Administration, Intravaginal; Anti-Infective Agents; Contraceptive Devices, Female; Female; HIV Infe | 2004 |
Necrotising ulcerative gingivitis/periodontitis as indicators of HIV-infection.
Topics: Acetaminophen; Adolescent; Adult; Analgesics, Non-Narcotic; Anti-Infective Agents; Anti-Infective Ag | 2004 |
Metastatic Crohn's disease mimicking genital pyoderma gangrenosum in an HIV patient.
Topics: Adult; Anti-Infective Agents; Anti-Inflammatory Agents; Crohn Disease; Diagnosis, Differential; Gran | 2005 |
The cost-effectiveness of treating male trichomoniasis to avert HIV transmission in men seeking sexually transmitted disease care in Malawi.
Topics: Adult; Animals; Community Health Services; Cost-Benefit Analysis; Disease Transmission, Infectious; | 2006 |
Amoebic hepatic abscesses in an HIV-positive patient.
Topics: Amebicides; Entamoebiasis; HIV Infections; Humans; Liver Abscess, Amebic; Male; Metronidazole; Middl | 2006 |
Recurrence of symptomatic bacterial vaginosis 12 months after oral metronidazole therapy in HIV-positive and -negative women.
Topics: Administration, Oral; Adult; Aged; Anti-Infective Agents; Female; Follow-Up Studies; HIV Infections; | 2006 |
Recurrence of symptomatic bacterial vaginosis 12 months after oral metronidazole therapy in HIV-positive and -negative women.
Topics: Administration, Oral; Adult; Aged; Anti-Infective Agents; Female; Follow-Up Studies; HIV Infections; | 2006 |
Recurrence of symptomatic bacterial vaginosis 12 months after oral metronidazole therapy in HIV-positive and -negative women.
Topics: Administration, Oral; Adult; Aged; Anti-Infective Agents; Female; Follow-Up Studies; HIV Infections; | 2006 |
Recurrence of symptomatic bacterial vaginosis 12 months after oral metronidazole therapy in HIV-positive and -negative women.
Topics: Administration, Oral; Adult; Aged; Anti-Infective Agents; Female; Follow-Up Studies; HIV Infections; | 2006 |
HIV and parasitic infection and the effect of treatment among adult outpatients in Malawi.
Topics: Adult; Albendazole; Ambulatory Care; Anthelmintics; Antiprotozoal Agents; CD4 Lymphocyte Count; Fece | 2007 |
Metronidazole-induced pancreatitis during HIV infection.
Topics: Acute Disease; Adult; Anti-Infective Agents; Enterocolitis, Pseudomembranous; HIV Infections; Homose | 2008 |
Association between amebic liver abscess and human immunodeficiency virus infection in Taiwanese subjects.
Topics: Adult; Aged; Antibodies, Protozoan; Antiprotozoal Agents; CD4 Lymphocyte Count; Comorbidity; HIV Inf | 2008 |
Spontaneous Salmonella peritonitis in HIV infection.
Topics: Adult; Anti-Bacterial Agents; Bacteremia; Female; HIV Infections; Humans; Metronidazole; Peritonitis | 1995 |
Persistent diarrhea caused by Isospora belli: therapeutic response to pyrimethamine and sulfadiazine.
Topics: Acquired Immunodeficiency Syndrome; Animals; Anti-Infective Agents; Antitrichomonal Agents; Diarrhea | 1996 |
Antibiotic and cholestyramine treatment of chronic diarrhea in HIV-infected children.
Topics: Anti-Bacterial Agents; Child; Child, Preschool; Cholestyramine Resin; Chronic Disease; Diarrhea; Dru | 1997 |
HIV associated eosinophilic folliculitis--differential diagnosis and management.
Topics: Administration, Topical; Anti-Infective Agents; Anti-Inflammatory Agents; Antifungal Agents; Eosinop | 1999 |
[Diarrhea in HIV infection].
Topics: Adult; Amebiasis; Amebicides; Anti-Infective Agents; Diarrhea; HIV Infections; Humans; Male; Metroni | 1999 |
Bacterial vaginosis and HIV infection.
Topics: Anti-Infective Agents; Female; HIV Infections; Humans; Metronidazole; Risk Factors; Vaginosis, Bacte | 2000 |
Vaginal candidiasis and other types of vaginitis.
Topics: Antifungal Agents; Candidiasis, Vulvovaginal; CD4 Lymphocyte Count; Clinical Trials as Topic; Female | 1995 |
Data on HIV infection in women expands.
Topics: Anti-Bacterial Agents; Azithromycin; Cefixime; Drug Administration Schedule; Drug Therapy, Combinati | 1999 |
Human immunodeficiency virus type 1 stimulatory activity by Gardnerella vaginalis: relationship to biotypes and other pathogenic characteristics.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacteriocins; Cells, Cultured; Drug Resistance, Microb | 2001 |
[Case of an HIV-patient with advanced form of perianal hidradenitis].
Topics: Adult; Anus Diseases; Hidradenitis; HIV Infections; Humans; Male; Metronidazole; Proctitis; Sigmoido | 2000 |
Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.
Topics: Adult; Anti-Bacterial Agents; Clostridioides difficile; Drug Resistance, Microbial; Enterocolitis, P | 2002 |
HIV-related gingival and periodontal disorders.
Topics: AIDS-Related Opportunistic Infections; Gingivitis; HIV Infections; Humans; Metronidazole; Periodonti | 1992 |
Papular pruritic eruption with human immunodeficiency virus infection.
Topics: Adult; Dermatitis; Female; HIV Infections; Humans; Metronidazole; Pruritus; Zidovudine | 1991 |